Investment Thesis
Vicapsys Life Sciences exhibits critical financial distress with negative stockholders equity of -2.6M, indicating technical insolvency. The company has no reported revenue, ongoing substantial losses (-752.7K net income), catastrophic liquidity (0.03x current ratio), and only 89.6K in cash against significant obligations, creating an imminent solvency crisis.
Strengths
- Minimal operational debt structure despite negative equity
- Still trading and operational, allowing potential for capital restructuring
- Pharmaceutical sector exposure could offer significant upside if any product-related assets emerge
Risks
- Negative stockholders equity of -2.6M indicating technical insolvency and liabilities exceed assets
- Critical liquidity crisis with 0.03x current ratio and only 89.6K cash against substantial current liabilities
- No reported revenue and persistent large losses (-752.7K net income, -585.0K operating loss) with negative free cash flow burning capital
- Imminent cash depletion risk given minimal cash position and ongoing negative cash burn of -43.7K
- Zero insider Form 4 activity suggests management has no confidence in company viability
- High probability of bankruptcy filing or dilutive emergency capital raise to avoid insolvency
Key Metrics to Watch
- Cash burn rate and remaining runway in weeks/months before depletion
- Any revenue generation or commercial partnership announcements
- Changes in stockholders equity trajectory toward positive territory
- Emergency capital raises, debt restructuring, or bankruptcy filings
- Patent filings or disclosed development-stage assets in SEC filings
Financial Metrics
Revenue
N/A
Net Income
-752.7K
EPS (Diluted)
$-0.02
Free Cash Flow
-43.7K
Total Assets
89.6K
Cash
89.6K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-840.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.03x
Quick Ratio
0.03x
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
-113.45x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-18T15:54:25.334041 |
Data as of: 2024-09-30 |
Powered by Claude AI